Program Description
In this CME-certified presentation, Ronald A. Figlin, MD, reviews the basic disease characteristics of renal cell carcinoma (RCC), the most important elements to consider when diagnosing RCC, and how the natural history of RCC has changed in recent years. Dr. Figlin begins by discussing the epidemiology of RCC across different patient subgroups, as well as environmental, clinical, and genetic risk factors that have been implicated in the etiology of RCC. He then explains the typical symptoms and histopathologic features of RCC, with a review of the 5 RCC subtypes. Dr. Figlin focuses heavily on the approach to RCC diagnosis by reviewing the role of noninvasive imaging, physical examination, laboratory work-up, other diagnostic methods, and RCC staging. The last topic he reviews includes the prognostic features associated with RCC, relative survival outcomes based on these factors, and models that have been developed that incorporate a variety of these factors to increase the accuracy of prognostic determinations.

Target Audience
This activity has been designed for community-and hospital-based medical oncologists, hematologists, urologists, nephrologists, and allied healthcare providers who provide medical care and support to patients with renal cell carcinoma.

Learning Objectives
After completing this program, participants should be able to

	•	Describe the epidemiology of renal cell carcinoma (RCC) across different patient subgroups, including risk factors for development
	•	Identify the appropriate techniques and methodologies used for RCC diagnosis and staging
	•	Discuss prognostic features associated with RCC and relative survival outcomes based on these factors

Faculty
Robert A. Figlin, MD (Activity Director)
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and Therapeutics Research
City of Hope National Medical Center and Beckman Research Institute
Associate Director for Clinical research
City of Hope Comprehensive Cancer Center
Duarte, California

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit
This activity is designated for .5 AMA Physicians’ Recognition Award™ credits. To receive your CME credits you are requested to review the material in full and take the post-test and evaluation. Your evaluation of the activity and comments will remain confidential.

Disclosure
City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational is provided below.

Robert A. Figlin, MD (Activity Director)

Commercial Interest	Relationship
Amgen, GlaxoSmithKline plc; Keryx Biopharmaceuticals, Inc.; Pfizer Inc; Wyeth	Grant/Research Support
Keryx Biopharmaceuticals, Inc; Pfizer Inc; Wyeth	Consultant

Dr. Figlin did not report specific mention of off-label and/or investigational product use, within his presentation.

References

1.	American Joint Committee on Cancer. Staging resources: TNM resource files – genitourinary sites: kidney. Accessed January 8, 2007, at http://www.cancerstaging.org/education/tnmschema/kidney.ppt.
2.	Bechtold RE, Zagoria RJ. Imaging approach to staging of renal cell carcinoma. Urol Clin North Am. 1997;24:507-522.
3.	Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11:71-77.
4.	Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006;175:859-863.
5.	Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197:589-597.
6.	Brennan JF, Stilmant MM, Babayan RK, Siroky MB. Acquired renal cystic disease: implications for the urologist. Br J Urol. 1991;67:342-348.
7.	Brierly RD, Thomas PJ, Harrison NW, Fletcher MS, Nawrocki JD, Ashton-Key M. Evaluation of fine-needle aspiration cytology for renal masses. BJU Int. 2000;85:14-18.
8.	Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
9.	Choueiri TK, Rini B, Garcia JA, et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol. 2007;18:249-255.
10.	Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305-1311.
11.	Chow WH, McLaughlin JK, Linet MS, Niwa S, Mandel JS. Use of analgesics and risk of renal cell cancer. Int J Cancer. 1994;59:467-470.
12.	Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol. 2003;169:71-74.
13.	Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol. 1991;145:248-250.
14.	Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
15.	Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314-319.
16.	Henriksson C, Haraldsson G, Aldenborg F, Lindberg S, Pettersson S. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol. 1992;26:363-366.
17.	Hricak H, Demas BE, Williams RD, et al. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology. 1985;154:709-715.
18.	Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114:101-108.
19.	Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging. 1991;32:69-118.
20.	Kabala JE, Gillatt DA, Persad RA, Penry JB, Gingell JC, Chadwick D. Magnetic resonance imaging in the staging of renal cell carcinoma. Br J Radiol. 1991;64:683-689.
21.	Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172:863-866.
22.	Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7:135-140.
23.	Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502-1510.
24.	Lornoy W, Becaus S, de Vleeschouwer M, et al. Renal cell carcinoma, a new complication of analgesic nephropathy. Lancet. 1986;1:1271-1272.
25.	Marshall ME, Pearson T, Simpson W, Butler K, McRoberts W. Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. Urology. 1990;36:300-302.
26.	McCredie M, Pommer W, McLaughlin JK, et al. International renal-cell cancer study. II. Analgesics. Int J Cancer. 1995;60:345-349.
27.	McDougal WS, Garnick MB. Clinical signs and symptoms of renal cell carcinoma. In Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds.), Comprehensive Textbook of Genitourinary Oncology, 2nd ed. New York: Lippincott, Williams, and Wilkins; 2000, p. 113.
28.	Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer. 1988;61(8):1639-1651.
29.	Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832-841.
30.	Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
31.	National Cancer Institute. SEER Cancer Statistics Fact Sheet: Cancer of the Kidney and Renal Pelvis. Accessed January 5, 2008, at http://seer.cancer.gov/statfacts/html/kidrp.html?statfacts_page=kidrp.html&x=16&y=22.
32.	Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol. 2007;177:430-436.
33.	Novick AC, Campbell SC. Renal tumors. In Walsh PC, Retick AB, Vaughan ED, Wein AJ (eds.), Campbell’s Urology. Philadelphia: WB Saunders; 2002, pp. 2672-2731.
34.	Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623.
35.	Patard JJ, Dorey FJ, Cindolo L, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004;172:2167-2171.
36.	Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22:3316-3322.
37.	Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763-2771.
38.	Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol. 2003;44:226-232.
39.	Patard JJ, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Prognostic significance of the mode of detection in renal tumours. BJU Int. 2002;90:358-363.
40.	Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:920-931.
41.	Ries LAG, Melbert D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
42.	Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer. 2007;109:868-874.
43.	Schlomer B, Figenshau RS, Yan Y, Venkatesh R, Bhayani SB. Pathological features of renal neoplasms classified by size and symptomatology. J Urol. 2006;176:1317-1320.
44.	Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology. 1996;48:692-695.
45.	Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166:932-940.
46.	Störkel S, van den Berg E. Morphological classification of renal cancer. World J Urol. 1995;13:153-158.
47.	Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006;107:1793-1800.
48.	Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125-143.
49.	Truong LD, Krishnan B, Cao JT, Barrios R, Suki WN. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis. 1995;26:1-12.
50.	Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000;163:426-430.
51.	Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090-1095.
52.	Zbar B, Glenn G, Merino M, et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol. 2007;177:461-465.
53.	Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649-1657.